Correlation of molecular markers with clinical outcome in gbm patients radiation treated with or without gefitinib

A method of determining a prognosis of a patient comprising:

• assessing the relative concentration of a protein biomarker in a tissue specimen obtained from the patient chosen from the group comprising:
• PTEN, EGFRvIII, EGFR, IGF-1R, and NFkB,
• wherein high levels of PTEN, EGFRvIII, EGFR, IGF-1R and/or NFkB indicate the patient has a relatively poor prognosis when treated with radiation therapy alone.

A method of determining a prognosis of a patient comprising:

• assessing the concentration of a protein biomarker in a tissue specimen obtained from the patient chosen from the group comprising:
• pAKT, pmTOR, pMAPK, and Src
• wherein high levels of nuclear pAKT, nuclear pMAPK, low levels of nuclear pmTOR and/or intermediate or high levels of Src indicate the patient has a relatively poor prognosis when treated with radiation therapy combined with gefitinib.

A method of determining a prognosis of a patient comprising:

• assessing the relative concentration of a protein biomarker in a tissue specimen obtained from the patient chosen from the group comprising:
• pAKT, pmTOR, and pMAPK,
• wherein high levels of nuclear pAKT, nuclear pMAPK, and/or low levels of nuclear pmTOR indicate the patient has a relatively poor prognosis when treated with radiation therapy combined with gefitinib.

A method of identifying a patient suitable for treatment with a gefitinib in combination with radiation therapy, comprising:

• assessing the relative concentration of one or more biomarkers in a tissue specimen obtained from the patient wherein high levels of one or more biomarkers indicates the patient is likely to benefit from treatment.

A method of determining a prognosis of a patient comprising:

• assessing the concentration, or the relative concentration of a protein biomarker in a tissue specimen obtained from the patient, the biomarker chosen from the group comprising:
• pAKT, PTEN, EGFRvIII, EGFR, IGF-1R, pmTOR, pMAPK, survivin, and/or NFkB,
• wherein an intermediate level of IGF-1R or NFkB or a high cytoplasmic to nuclear ratio of pAKT indicate the patient has a relatively poor prognosis when treated with radiation therapy alone.

A method of determining a prognosis of a patient comprising:

• assessing the concentration, or the relative concentration of a protein biomarker in a tissue specimen obtained from the patient, the biomarker chosen from the group comprising:
• pAKT, PTEN, EGFRvIII, EGFR, IGF-1R, pmTOR, pMAPK, survivin, and/or NFkB,
• wherein a high nuclear pMAPK or intermediate cytopslasm to nuclear PTEN ratio indicate the patient has a relatively good prognosis when treated with radiation therapy alone.

A method of determining a prognosis of a patient comprising:

• assessing the concentration, or the relative concentration of a protein biomarker in a tissue specimen obtained from the patient, the biomarker chosen from the group comprising:
• pAKT, PTEN, EGFRvIII, EGFR, IGF-1R, pmTOR, pMAPK, survivin, Src and/or NFkB,
• wherein an intermediate level of EGFR, high level of NFkB and/or intermediate to high Src level indicate the patient has a relatively poor prognosis when treated with radiation therapy combined with gefitinib.

A method of determining a prognosis of a patient comprising:

• assessing the concentration, or the relative concentration of a protein biomarker in a tissue specimen obtained from the patient, the biomarker chosen from the group comprising:
• pAKT, PTEN, EGFRvIII, EGFR, IGF-1R, pmTOR, pMAPK, survivin, Src, and/or NFkB,
• wherein an relatively high or low EGFR levels, low Src levels and/or low to intermediate NFkB indicate the patient has a relatively good prognosis when treated with radiation therapy combined with gefitinib.

A method of determining the prognosis or relative risk of a patient, comprising assessing the relative concentration of pAKT, PTEN, EGFRvIII, EGFR, IGF-1R, pmTOR, pMAPK, survivin, and/or NFkB, protein biomarkers in a tissue specimen obtained from the patient, wherein expression or AQUA® score of each biomarker on a continuous scale is put into a Cox regression model for continuous variables resulting in a calculation of overall patient risk.

A method of determining the prognosis or relative risk of a patient, comprising assessing the relative concentration of pAKT, PTEN, EGFRvIII, EGFR, IGF-1R, pmTOR, pMAPK, survivin, and/or NFkB, protein biomarkers in a tissue specimen obtained from the patient, wherein expression or AQUA® score of each biomarker is first categorized based on optimal univariate cutpoints, then applied to a Cox regression model for categorical variables resulting in a calculation of overall patient risk.